RecruitingNCT06592989
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
Studying Serotonin-producing neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Principal Investigator
- Jiuliang Yan, M.D.Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Intervention
- sorafenib, gefitinib(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Shanghai General Hospital, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06592989 on ClinicalTrials.govOther trials for Serotonin-producing neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
See all trials for Serotonin-producing neuroendocrine tumor of pancreas →